Literature DB >> 25937766

Borderline resectable pancreatic cancer.

Bhargava Mullapudi1, Patrick J Hawkes1, Asish Patel1, Chandrakanth Are1, Subhasis Misra2.   

Abstract

Borderline resectable pancreatic cancer (BRPC) is an evolving diagnostic entity that blurs the distinction between resectable and locally advanced pancreatic cancer (Varadhachary et al. Ann Surg Oncol 13:1035-1046, 2006). Until recently the management of this disease has been poorly defined; however, consensus guidelines have been developed regarding the proper management of this diagnostic entity. Recent studies have shown that if appropriately identified and treated, this subset of disease can have outcomes similar to pancreatic cancer that is defined as resectable (Laurence et al. J Gastrointest Surg 15:2059-2069, 2011). The aim of this review is to outline the current consensus on definitions, workup and management of BRPC, and also provide a summary of issues that require progress as defined by the International Study Group of Pancreatic Surgery (ISGPS).

Entities:  

Keywords:  Borderline; Pancreas; Pancreatic cancer; Pancreaticoduodenectomy; Whipple

Year:  2015        PMID: 25937766      PMCID: PMC4412859          DOI: 10.1007/s13193-014-0374-8

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  36 in total

1.  Preoperative staging of cancer of the pancreatic head: is there room for improvement?

Authors:  Kristopher P Croome; Shiva Jayaraman; Christopher M Schlachta
Journal:  Can J Surg       Date:  2010-06       Impact factor: 2.089

2.  Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion.

Authors:  Hui Li; Meng Su Zeng; Kang Rong Zhou; Da Yong Jin; Wen Hui Lou
Journal:  J Comput Assist Tomogr       Date:  2005 Mar-Apr       Impact factor: 1.826

3.  Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Authors:  Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

Review 4.  How to define and manage borderline resectable pancreatic cancer.

Authors:  Pavlos Papavasiliou; Yun Shin Chun; John P Hoffman
Journal:  Surg Clin North Am       Date:  2013-03-27       Impact factor: 2.741

5.  Role of endoscopic ultrasound and magnetic resonance imaging in the preoperative staging of pancreatic adenocarcinoma.

Authors:  N A Ahmad; J D Lewis; E S Siegelman; E F Rosato; G G Ginsberg; M L Kochman
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

6.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

7.  Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma.

Authors:  Saburo Fukuda; Elie Oussoultzoglou; Philippe Bachellier; Edoardo Rosso; Hiroshi Nakano; Maxime Audet; Daniel Jaeck
Journal:  Arch Surg       Date:  2007-02

8.  Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA.

Authors:  Carlos Micames; Paul S Jowell; Rebekah White; Erik Paulson; Rendon Nelson; Michael Morse; Herbert Hurwitz; Theodore Pappas; Douglas Tyler; Kevin McGrath
Journal:  Gastrointest Endosc       Date:  2003-11       Impact factor: 9.427

Review 9.  Borderline resectable pancreatic cancer: on the edge of survival.

Authors:  Gregory M Springett; Sarah E Hoffe
Journal:  Cancer Control       Date:  2008-10       Impact factor: 3.302

10.  Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy.

Authors:  Brian G Turner; Sevdenur Cizginer; Deepak Agarwal; Jingyun Yang; Martha Bishop Pitman; William R Brugge
Journal:  Gastrointest Endosc       Date:  2010-01       Impact factor: 9.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.